India approves Oxford-AstraZeneca and Bharat BioTech's Covaxin COVID-19 vaccines for emergency use | Business Upturn

India approves Oxford-AstraZeneca and Bharat BioTech’s Covaxin COVID-19 vaccines for emergency use

The Drugs Controller General of India (DCGI) in a press conference at the National Media Centre approved the Oxford-AstraZeneca COVID-19 vaccine and Bharat Biotech’s Covaxin for emergency use on Sunday. Bharat BioTech’s Covaxin is India’s one of the first vaccines against the novel Coronavirus.

DCGI VG Somani said, “Both the drug firms have submitted data on their trial runs and both have been granted permission for “restricted use”. The overall efficacy of the Oxford-AstraZeneca COVID-19 vaccine was 70.42%, while Bharat Biotech’s Covaxin was “safe and provides a robust immune response.”

He added by saying that they’ll never approve anything if there is slightest of safety concern. The vaccines are 100% safe. Some side effects like mild fever, pain and allergy are common for every vaccine. It (people may get impotent) is absolute rubbish.

Prime Minister Narendra Modi congratulated the hardworking scientists and innovators in India after the vaccines received emergency approval, 

The country has been preparing for a COVID-19 vaccine rollout for the last four months.

Meanwhile, India recorded 18,177 fresh Coronavirus infections today, taking the country’s tally to 1,03,23,965, including 2,47,220 active cases. The death toll after 217 new fatalities stands at 1,49,435. 20,923 new recoveries pushed the total number of recoveries to 99,27,310.